Trade Kymera Therapeutics, Inc. - KYMR CFD

Add to favourite

33.92

3.36%

View detailed chart

To be able to trade stocks like this, create an account and apply for a stock listing.

Create Account

Summary
Historical Data
Events
Income Statement
Balance Sheet
Cash Flow

Trading сonditions

Spread

0.10

Long position overnight fee

-0.026179%

Short position overnight fee

0.003957%

Overnight fee time

21:00 (UTC)

Min traded quantity

Currency

USD

Margin

Stock exchange

United States of America

Commission on trade

*Information provided by Capital.com

Kymera Therapeutics Inc ESG Risk Ratings

High Medium Low Negligible

‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats

Prev. Close*	35.1
Open*	34.65
1-Year Change*	-0.35%
Day's Range*	33.33 - 35.27
52 wk Range	9.60-39.85
Average Volume (10 days)	1.22M
Average Volume (3 months)	19.08M
Market Cap	1.61B
P/E Ratio	-100.00K
Shares Outstanding	59.33M
Revenue	46.85M
EPS	-2.88
Dividend (Yield %)	N/A
Beta	2.21
Next Earnings Date	Feb 21, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

Last Week
Last Month
Last Year
Last two Years
Max

Daily
Weekly
Monthly

Date	Close	Change	Change (%)	Open	High	Low
Apr 19, 2024	33.92	-0.59	-1.71%	34.51	35.30	33.24
Apr 18, 2024	35.10	1.96	5.91%	33.14	35.50	33.14
Apr 17, 2024	33.69	-0.22	-0.65%	33.91	34.11	33.10
Apr 16, 2024	33.87	0.14	0.42%	33.73	34.67	33.29
Apr 15, 2024	34.33	-1.18	-3.32%	35.51	35.66	34.16
Apr 12, 2024	35.54	-0.39	-1.09%	35.93	36.78	34.69
Apr 11, 2024	37.16	1.63	4.59%	35.53	37.22	35.28
Apr 10, 2024	35.25	-0.28	-0.79%	35.53	36.32	35.01
Apr 9, 2024	37.56	1.27	3.50%	36.29	37.58	35.91
Apr 8, 2024	36.30	-0.08	-0.22%	36.38	36.86	35.56
Apr 5, 2024	36.36	0.65	1.82%	35.71	37.12	35.16
Apr 4, 2024	36.15	-1.16	-3.11%	37.31	37.91	35.96
Apr 3, 2024	36.99	-0.92	-2.43%	37.91	37.91	36.49
Apr 2, 2024	37.56	-0.48	-1.26%	38.04	38.50	36.71
Apr 1, 2024	39.32	-0.99	-2.46%	40.31	40.31	38.14
Mar 28, 2024	40.13	0.00	0.00%	40.13	40.53	39.24
Mar 27, 2024	40.09	1.04	2.66%	39.05	40.17	38.89
Mar 26, 2024	39.40	-0.38	-0.96%	39.78	40.20	38.94
Mar 25, 2024	39.42	-0.44	-1.10%	39.86	41.20	39.20
Mar 22, 2024	40.62	1.45	3.70%	39.17	41.20	39.17

Kymera Therapeutics, Inc. Events

Time (UTC)	Country	Event
Thursday, May 2, 2024
Time (UTC) 12:30	Country US	Event Q1 2024 Kymera Therapeutics Inc Earnings Release Q1 2024 Kymera Therapeutics Inc Earnings Release Forecast - Previous -
Friday, June 14, 2024
Time (UTC) 13:00	Country US	Event Kymera Therapeutics Inc Annual Shareholders Meeting Kymera Therapeutics Inc Annual Shareholders Meeting Forecast - Previous -
Thursday, August 1, 2024
Time (UTC) 12:30	Country US	Event Q2 2024 Kymera Therapeutics Inc Earnings Release Q2 2024 Kymera Therapeutics Inc Earnings Release Forecast - Previous -

View all events

Annual
Quarterly

	2022	2021	2020	2019	2018
Total revenue	46.826	72.832	34.034	2.934	0
Revenue	46.826	72.832	34.034	2.934	0
Total Operating Expense	208.082	173.362	80.338	45.139	21.451
Selling/General/Admin. Expenses, Total	43.834	36.345	18.233	7.981	3.772
Research & Development	164.248	137.017	62.105	37.158	17.679
Operating Income	-161.256	-100.53	-46.304	-42.205	-21.451
Interest Income (Expense), Net Non-Operating	6.448	0.313	0.711	0.959	-0.016
Net Income Before Taxes	-154.808	-100.217	-45.593	-41.246	-21.467
Net Income After Taxes	-154.808	-100.217	-45.593	-41.246	-21.467
Net Income Before Extra. Items	-154.808	-100.217	-45.593	-41.246	-21.467
Net Income	-154.808	-100.217	-45.593	-41.246	-21.467
Income Available to Common Excl. Extra. Items	-154.808	-100.217	-54.643	-41.246	-21.467
Income Available to Common Incl. Extra. Items	-154.808	-100.217	-54.643	-41.246	-21.467
Diluted Net Income	-154.808	-100.217	-54.643	-41.246	-21.467
Diluted Weighted Average Shares	53.9332	47.989	44.4822	43.1386	43.1386
Diluted EPS Excluding Extraordinary Items	-2.87036	-2.08833	-1.22842	-0.95613	-0.49763
Dividends per Share - Common Stock Primary Issue			0	0	0
Diluted Normalized EPS	-2.87036	-2.08833	-1.22842	-0.95613	-0.49763
Total Adjustments to Net Income		0	-9.05

	Jun 2023	Mar 2023	Dec 2022	Sep 2022	Jun 2022
Total revenue	16.513	9.466	16.139	9.551	11.514
Revenue	16.513	9.466	16.139	9.551	11.514
Total Operating Expense	59.896	54.792	54.769	54.433	52.324
Selling/General/Admin. Expenses, Total	14.129	12.565	11.636	10.556	11.031
Research & Development	45.767	42.227	43.133	43.877	41.293
Operating Income	-43.383	-45.326	-38.63	-44.882	-40.81
Interest Income (Expense), Net Non-Operating	4.584	4.398	3.765	1.88	0.553
Net Income Before Taxes	-38.799	-40.928	-34.865	-43.002	-40.257
Net Income After Taxes	-38.799	-40.928	-34.865	-43.002	-40.257
Net Income Before Extra. Items	-38.799	-40.928	-34.865	-43.002	-40.257
Net Income	-38.799	-40.928	-34.865	-43.002	-40.257
Total Adjustments to Net Income
Income Available to Common Excl. Extra. Items	-38.799	-40.928	-34.865	-43.002	-40.257
Income Available to Common Incl. Extra. Items	-38.799	-40.928	-34.865	-43.002	-40.257
Diluted Net Income	-38.799	-40.928	-34.865	-43.002	-40.257
Diluted Weighted Average Shares	58.327	58.187	57.9326	54.5355	51.7724
Diluted EPS Excluding Extraordinary Items	-0.6652	-0.70339	-0.60182	-0.78851	-0.77758
Dividends per Share - Common Stock Primary Issue	0	0		0	0
Diluted Normalized EPS	-0.6652	-0.70339	-0.60182	-0.78851	-0.77758

Annual
Quarterly

	2022	2021	2020	2019	2018
Total Current Assets	419.416	451.273	302.339	92.845	41.79
Cash and Short Term Investments	407.166	442.418	296.202	91.957	41.26
Cash & Equivalents	68.395	47.976	31.004	76.015	41.26
Short Term Investments	338.771	394.442	265.198	15.942	0
Total Receivables, Net	2.537	0.135	1.433	0	0.148
Prepaid Expenses	9.713	8.72	4.704	0.888	0.382
Total Assets	603.134	605.905	487.175	116.702	44.231
Property/Plant/Equipment, Total - Net	22.243	21.307	20.686	22.083	2.242
Property/Plant/Equipment, Total - Gross	29.136	25.223	22.833	23.132	2.466
Accumulated Depreciation, Total	-6.893	-3.916	-2.147	-1.049	-0.224
Other Long Term Assets, Total	9.147	8.138	1.619	1.774	0.199
Total Current Liabilities	71.343	92.542	110.617	34.57	4.687
Accounts Payable	4.335	4.005	4.368	3.276	2.056
Accrued Expenses	29.63	25.08	12.896	7.175	2.225
Notes Payable/Short Term Debt	0	0	0	0	0
Current Port. of LT Debt/Capital Leases	1.408	1.138	0.689	0.681	0.302
Other Current Liabilities, Total	35.97	62.319	92.664	23.438	0.104
Total Liabilities	112.983	146.267	203.287	82.028	5.238
Total Long Term Debt	1.246	1.14	0.604	1.165	0.393
Capital Lease Obligations	1.246	1.14	0.604	1.165	0.393
Other Liabilities, Total	40.394	52.585	92.066	46.293	0.158
Total Equity	490.151	459.638	283.888	34.674	38.993
Redeemable Preferred Stock				109.08	73.429
Common Stock	0.006	0.005	0.004	0	0
Additional Paid-In Capital	878.884	689.275	412.777	2.044	0.774
Retained Earnings (Accumulated Deficit)	-383.79	-228.982	-128.765	-76.456	-35.21
Other Equity, Total	-4.949	-0.66	-0.128	0.006	0
Total Liabilities & Shareholders’ Equity	603.134	605.905	487.175	116.702	44.231
Total Common Shares Outstanding	55.0394	51.5362	44.4822	43.1386	43.1386
Accounts Receivable - Trade, Net	2.537	0.135	0.856
Long Term Investments	152.328	125.187	162.531

	Sep 2023	Jun 2023	Mar 2023	Dec 2022	Sep 2022
Total Current Assets	375.694	385.402	411.55	419.416	494.022
Cash and Short Term Investments	357.825	367.574	396.877	407.166	481.908
Cash & Equivalents	81.051	52.386	50.152	68.395	155.658
Short Term Investments	276.774	315.188	346.725	338.771	326.25
Total Receivables, Net	3.778	4.122	3.32	2.537	2.882
Accounts Receivable - Trade, Net	3.778	4.122	3.32	2.537	2.882
Prepaid Expenses	14.091	13.706	11.353	9.713	9.232
Total Assets	552.378	581.945	613.905	603.134	638.472
Property/Plant/Equipment, Total - Net	91.1	83.181	74.036	22.243	21.617
Property/Plant/Equipment, Total - Gross	100.649	91.872	81.827	29.136	27.692
Accumulated Depreciation, Total	-9.549	-8.691	-7.791	-6.893	-6.075
Long Term Investments	76.988	104.759	119.017	152.328	113.701
Other Long Term Assets, Total	8.596	8.603	9.302	9.147	9.132
Total Current Liabilities	63.166	54.602	61.933	71.343	91.124
Accounts Payable	4.978	3.745	6.483	4.335	6.327
Accrued Expenses	25.655	22.939	19.53	29.63	27.015
Notes Payable/Short Term Debt	0	0	0	0	0
Current Port. of LT Debt/Capital Leases	1.01	1.231	1.339	1.408	1.103
Other Current Liabilities, Total	31.523	26.687	34.581	35.97	56.679
Total Liabilities	156.843	146.517	151.9	112.983	125.587
Total Long Term Debt	0.643	0.762	0.989	1.246	0.69
Capital Lease Obligations	0.643	0.762	0.989	1.246	0.69
Other Liabilities, Total	93.034	91.153	88.978	40.394	33.773
Total Equity	395.535	435.428	462.005	490.151	512.885
Common Stock	0.006	0.006	0.006	0.006	0.006
Additional Paid-In Capital	914.363	902.574	889.755	878.884	867.717
Retained Earnings (Accumulated Deficit)	-516.384	-463.517	-424.718	-383.79	-348.925
Other Equity, Total	-2.45	-3.635	-3.038	-4.949	-5.913
Total Liabilities & Shareholders’ Equity	552.378	581.945	613.905	603.134	638.472
Total Common Shares Outstanding	55.4502	55.3903	55.2762	55.0394	54.7514

Annual
Quarterly

	2022	2021	2020	2019	2018
Net income/Starting Line	-154.808	-100.217	-45.593	-41.246	-21.467
Cash From Operating Activities	-153.085	-128.946	88.13	17.905	-17.863
Cash From Operating Activities	2.977	2.397	1.763	0.825	0.205
Non-Cash Items	36.369	30.797	7.093	1.639	1.091
Cash Interest Paid	0.179	0.158	0.115	0.046	0.015
Changes in Working Capital	-37.623	-61.923	124.867	56.687	2.308
Cash From Investing Activities	20.519	-99.835	-422.588	-16.486	-1.356
Capital Expenditures	-2.836	-1.597	-9.096	-0.532	-1.356
Other Investing Cash Flow Items, Total	23.355	-98.238	-413.492	-15.954	0
Cash From Financing Activities	152.999	250.28	289.262	34.911	52.932
Issuance (Retirement) of Stock, Net	154.129	249.18	276.289	35.282	53.227
Issuance (Retirement) of Debt, Net	-1.13	-0.849	-0.554	-0.371	-0.295
Net Change in Cash	20.433	21.499	-45.196	36.33	33.713
Financing Cash Flow Items	0	1.949	13.527

	Mar 2023	Dec 2022	Sep 2022	Jun 2022	Mar 2022
Net income/Starting Line	-40.928	-154.808	-119.943	-76.941	-36.684
Cash From Operating Activities	-43.968	-153.085	-113.549	-79.28	-40.295
Cash From Operating Activities	0.879	2.977	2.159	1.392	0.687
Non-Cash Items	8.059	36.369	28.365	19.347	9.048
Cash Interest Paid	0.052	0.179	0.124	0.086	0.046
Changes in Working Capital	-11.978	-37.623	-24.13	-23.078	-13.346
Cash From Investing Activities	24.584	20.519	70.185	107.666	25.863
Capital Expenditures	-4.009	-2.836	-2.463	-1.217	-0.482
Other Investing Cash Flow Items, Total	28.593	23.355	72.648	108.883	26.345
Cash From Financing Activities	1.159	152.999	151.046	0.549	0.185
Financing Cash Flow Items		0	0	0	0
Issuance (Retirement) of Stock, Net	1.486	154.129	151.871	1.082	0.449
Issuance (Retirement) of Debt, Net	-0.327	-1.13	-0.825	-0.533	-0.264
Net Change in Cash	-18.225	20.433	107.682	28.935	-14.247

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission

Leverage

1:1

20
100
500
1000
10000

Investment

Trade size (Leverage x Investement):

Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Kymera Therapeutics, Inc. Company profile

About Kymera Therapeutics Inc

Kymera Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. Its targeted protein degradation (TPD) platform Pegasus, allows it to discover selective small molecule protein degraders with activity against disease-causing proteins throughout the body. The Company’s Pegasus platform includes E3 Ligase Whole-Body Atlas, E3 Ligase Binders Toolbox, Ternary Complex Modeling, Quantitative System Pharmacology Model and Chemistry. Its clinical stage programs include IRAK4, IRAKIMiD, and STAT3, which each address targets within the interleukin-1 receptor/toll-like receptor (IL-1R/TLR), and janus kinase/signal transducers and activators of transcription (JAK/STAT). Its programs focus on treating range of immune-inflammatory diseases, hematologic malignancies, and solid tumors.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Kymera Therapeutics Inc revenues increased from $34M to $72.8M. Net loss applicable to common stockholders increased 83% to $100.2M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development - increase from $59.8M to $125.3M (expense).

Industry:

Biotechnology & Medical Research (NEC)

200 Arsenal Yards Blvd., Suite 230
WATERTOWN
MASSACHUSETTS 02472
US

Income Statement

Annual
Quarterly

News

Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported

Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.

07:56, 17 April 2024

US Earnings Season : JP Morgan, Citigroup, Wells Fargo

The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.

16:03, 11 April 2024

Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues

The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.

09:22, 11 April 2024

US CPI Preview: US inflation expected to grind lower amid fears about sticky prices

US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).

15:11, 9 April 2024